PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

PreLiminary experiences in applying M-VAC neoadjuvant chemotherapy in patients with advanced cancer of urinary bladder (T2-T4)
Article published in Urologia Polska 1991/44/3.

authors

Andrzej Borkowski, Jędrzej Michalec, Adam Pawinski, Danuta Gajl, Grzegorz Madej, Tadeusz Krzeski
Z Katedry i Kliniki Urologii Instytutu Chirurgii AM w Warszawie
Kierownik Kliniki: prof. dr hab. med. T. Krzeski
Dyrektor Instytutu: prof. dr hab. med. M. Szostek
Z Zakładu Radioterapii Centrum Onkologii w Warszawie
Kierownik Zakładu: prof. dr hab. med. A. Hliniak
Z Zespołu Chemioterapii Centrum Onkologii w Warszawie
Kierownik Zespołu: doc. dr hab. med. G. Madej
Dyrektor Instytutu: prof. dr hab. med. J. Steffen

summary

The authors present preliminary opinions on the application of M-VAC neo-adjuvant chemotherapy in 36 patients with infiltrating tumours of urinary bladder. Comparing the effect of chemotherapy after 2 courses, assessed cytoscopically, with the fates of patients in respect to further treatment applied, it is suggested that in patients with total tumour remission after 2 courses the proper procedure should be cystectomy or irradiation of bladder. Continuation of systemic chemotherapy seems to be justafied only in patients in whom cystoscopic picture shows Considerable decrease of the tumour size. Patients with no response after 2 courses of chemotherapy have poor prognoises.

references

  1. 1. Klimberg I., Wajsman Z.: Treatment for muscle ¶nvasive carcinoma ,of the bladder. J. Urol., 1986, 136, 1169. —
  2. 2 .McCullo D., Cooper R., Yeman L., Loo-m±er L., Woodruff R., Boyce W., Harrison L,, Assimos D., Lynch D.: Neoadju-vant treatment osf stage T2 to T4 bladder cancer with cisplatinum, cyclophostpha-mide and doxorubicin. J. Urol., 1989, 141, 849. —
  3. 3. Raghavan D., Pearson B., Duwal P., Rogers J,, Meager M., Wines R., Mameghan H., Boulas J., Green I.: Initial intravenous cisplatinum therapy: imiproved management for invtasive high risk bladder cancer. J. Urol., 1985, 133, 3-99. —
  4. 4. Scher H., Herr H., Sternberg C, Fair W., Bosi C, Morse M, Sogani P., Watson R., Dershaw D., Reuter V., Cur-ley T., Vaughan E., Whitemore W., Yagoda A.: Neo-adjuvant chemotherapy of invasive bladder cancer. Experience with the M-VAC regimen. Brit. J. Urol., 1989, 64, 250. —
  5. 5. Scher H., Yagoda A., Herr H., Sternberg C, Bosi C, Morse M., Sogani P., Watson R., Dersha D., Reuter V., Geller N., Hollander P., Vaughan E., Whitmore W., Fair W.: Neoadjuvant M-VAC (methotrexate, winblastine, doxorubi-ci and cisplatin) effect on the primary bladder lesion. J. Urol., 1988, 139, 470. —
  6. 6. Skinner D., Lieskovsky G.: Diagnosis and management of genitourinary cancer. W. B. Saunders Company. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo, 1S88, 318. —
  7. 7. Sternberg C, Yagoda A., Scher H., Watson R., Ahmed T., Weiselberg L., Geller N., Hollander P., Herr H., Sogani P., Morse M,, Whitmore W.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol, 1985, 133, 403. —
  8. 8. Szkodny A., Praisner A., Zieliński J.: Naciekaj±cy rak pęcherza moczowego (T2, T3, T4) w Polsce. Urol. Pol., 1989, 3, 3.

correspondence

prof. dr hab. med. Andrzej Borkowski. Klinika Urol. 02-005 Warszawa, ul. Lindleya 4